Ever since the potent defense elicited by the immune system was recognized, the treatment of cancer seemed easy to achieve and very promising. It is neither. Malignant growth is usually not very immunogenic and even if and when recognized as non-self (and therefore worthy of attack), the host?s immune response is feeble and insufficient. Only during the recent years, our insight into the molecular biology of cancer allows a more targeted and rational approach. Systemic immunotherapy is now in an experimental stage, using intratumoral injections of IFN-beta encoding, baculovirus-transduced High Five insect cells.
Go to Previous Page
Go to Next Page